No Data Yet
LongBio-B (01779.HK) closed up 57.1% at $150.9 on the gray market ahead of its June 5 Hong Kong IPO listing.
Clinical-stage biopharmaceutical company LONGBIO-B launches its Hong Kong IPO at HKD96.06 per share with nine cornerstone investors committing USD87 million.